Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TA 270

Drug Profile

TA 270

Alternative Names: TA-270

Latest Information Update: 06 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dainippon Ink & Chemicals
  • Developer Mariposa Health Limited
  • Class Antiallergics; Antiasthmatics; Quinolones
  • Mechanism of Action 5-lipoxygenase inhibitors; Antioxidants; Free radical scavengers; Immunosuppressants; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Chronic obstructive pulmonary disease

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease
  • Preclinical Cystic fibrosis

Most Recent Events

  • 06 Feb 2018 Preclinical trials in Asthma in Australia (Inhalation) (Mariposa health pipeline, February 2018)
  • 06 Feb 2018 Preclinical trials in Chronic obstructive pulmonary disease in Australia (Inhalation) (Mariposa health pipeline, February 2018)
  • 06 Feb 2018 Preclinical trials in Cystic fibrosis in Australia (Mariposa health pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top